The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment ...

Ozzy Osbourne has been remembered as a “pioneer,” a “fearless talent” and a “dear friend,” in an outpouring of tributes from ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...

GSK said the U.S. Food and Drug Administration extended its review period for Blenrep combinations to treat patients with relapsed or refractory multiple myeloma.

Early Anthropic hire raises $15M for AIUC to insure AI agents, helping enterprises deploy artificial intelligence securely with risk coverage and safety standards.

GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...

Enterprises will not see immediate impact from the AI Action Plan, but it signals wider support for open-source models and evaluations.

(Alliance News) - GSK PLC on Wednesday said the US Food & Drug Administration has extended the review period for Blenrep combinations in relapsed/refractory multiple myeloma after an advisory ...

Today, as European stocks benefit more from the optimism that the US-Japan deal will create for the trade outlook, the FTSE ...

SAP posts 37% EPS growth and 24% cloud revenue surge, but shares slip after mixed Q2 results and currency concerns.